Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Organisation › Details

Adaptimmune (Group)

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the Company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. As of October 31, 2015, 86 patients had been treated with Adaptimmune’s NY-ESO affinity enhanced T-cell therapy: 48 under Adaptimmune’s IND, and 38 under a National Cancer Institute IND. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs and its next affinity enhanced T-cell therapy, directed at MAGE-A10, is scheduled to enter the clinic shortly. The Company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 of these through unpartnered research programs. Adaptimmune has over 190 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. *

 

Period Start 2008-01-01 established
Products Industry BIOTECH
  Industry 2 TCR engineered T-cells
Persons Person Noble, James (Adaptimmune CEO before MediGene 200609–200809 before Avidex)
  Person 2 Knowles, Jonathan (Adaptimmune 201311– Executive Board Chairman before non-exec Director + Roche Head Global Research)
     
Region Region Abingdon, Oxfordshire
  Country United Kingdom (GB)
  Street 57 Jubilee Avenue
  City OX14 4RX Abingdon, Oxfordshire
  Tel +44-1235-438642
    Address record changed: 2018-07-24
     
Basic data Employees D: 101 to 500 (2017-12-31)
  Currency GBP
  Annual sales 37,833,000 (revenues, consolidated (2017) 2017-12-31)
  Profit -71,308,000 (2017-12-31)
  Cash 84,043,000 (2017-12-31)
     
    * Document for �About Section�: Adaptimmune Therapeutics plc. (11/12/15). "Press Release: Adaptimmune to Participate in the Jefferies Autumn 2015 Global Healthcare Conference". Philadeliphia, PA & Oxford.
     
   
Record changed: 2018-10-31

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Adaptimmune (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BIO Deutschland German Biotech Days 2019 Würzburg 600x60px




» top